Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.21
AZN's Cash-to-Debt is ranked lower than
77% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. AZN: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
AZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 2.73 Max: N/A
Current: 0.21
Equity-to-Asset 0.21
AZN's Equity-to-Asset is ranked lower than
91% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
AZN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.43 Max: 0.59
Current: 0.21
0.21
0.59
Interest Coverage 7.35
AZN's Interest Coverage is ranked lower than
77% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. AZN: 7.35 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 4.19  Med: 8.2 Max: 19.13
Current: 7.35
4.19
19.13
Piotroski F-Score: 4
Altman Z-Score: 1.64
Beneish M-Score: -2.42
WACC vs ROIC
5.99%
17.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 21.99
AZN's Operating Margin % is ranked higher than
83% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. AZN: 21.99 )
Ranked among companies with meaningful Operating Margin % only.
AZN' s Operating Margin % Range Over the Past 10 Years
Min: 8.05  Med: 28.16 Max: 38.09
Current: 21.99
8.05
38.09
Net Margin % 15.64
AZN's Net Margin % is ranked higher than
80% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. AZN: 15.64 )
Ranked among companies with meaningful Net Margin % only.
AZN' s Net Margin % Range Over the Past 10 Years
Min: 4.64  Med: 19.12 Max: 29.72
Current: 15.64
4.64
29.72
ROE % 25.65
AZN's ROE % is ranked higher than
88% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. AZN: 25.65 )
Ranked among companies with meaningful ROE % only.
AZN' s ROE % Range Over the Past 10 Years
Min: 5.9  Med: 31.4 Max: 45.52
Current: 25.65
5.9
45.52
ROA % 5.63
AZN's ROA % is ranked higher than
62% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. AZN: 5.63 )
Ranked among companies with meaningful ROA % only.
AZN' s ROA % Range Over the Past 10 Years
Min: 2.2  Med: 12.84 Max: 18.34
Current: 5.63
2.2
18.34
ROC (Joel Greenblatt) % 63.32
AZN's ROC (Joel Greenblatt) % is ranked higher than
89% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. AZN: 63.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 30.37  Med: 119.25 Max: 199.64
Current: 63.32
30.37
199.64
3-Year Revenue Growth Rate 5.10
AZN's 3-Year Revenue Growth Rate is ranked lower than
53% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. AZN: 5.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.9  Med: 4.4 Max: 19.9
Current: 5.1
-7.9
19.9
3-Year EBITDA Growth Rate 0.90
AZN's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. AZN: 0.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 10.9 Max: 24.8
Current: 0.9
-30.1
24.8
3-Year EPS without NRI Growth Rate 21.10
AZN's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. AZN: 21.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AZN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: 12.9 Max: 73.1
Current: 21.1
-48.9
73.1
GuruFocus has detected 8 Warning Signs with AstraZeneca PLC $AZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AZN's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AZN Guru Trades in Q2 2016

David Dreman 1,321 sh (New)
Ken Fisher 338,979 sh (+45.23%)
Jeremy Grantham 587,200 sh (+43.82%)
Dodge & Cox 32,532,723 sh (+24.89%)
PRIMECAP Management 15,365,950 sh (+17.44%)
NWQ Managers 572,985 sh (+13.06%)
Jim Simons 5,966,100 sh (+4.99%)
Pioneer Investments 447,226 sh (+0.16%)
Francis Chou 13,000 sh (unchged)
John Hussman 2,000 sh (unchged)
Murray Stahl 28,302 sh (unchged)
Manning & Napier Advisors, Inc 487,770 sh (unchged)
» More
Q3 2016

AZN Guru Trades in Q3 2016

Andreas Halvorsen 4,175,587 sh (New)
Ken Fisher 1,977,585 sh (+483.39%)
NWQ Managers 839,815 sh (+46.57%)
Dodge & Cox 42,189,973 sh (+29.68%)
PRIMECAP Management 17,313,325 sh (+12.67%)
Manning & Napier Advisors, Inc 495,960 sh (+1.68%)
Jeremy Grantham 594,800 sh (+1.29%)
Francis Chou 13,000 sh (unchged)
David Dreman 1,321 sh (unchged)
Murray Stahl 28,302 sh (unchged)
John Hussman 2,000 sh (unchged)
Pioneer Investments 446,742 sh (-0.11%)
Jim Simons 5,702,700 sh (-4.41%)
» More
Q4 2016

AZN Guru Trades in Q4 2016

Steven Cohen 676,000 sh (New)
Pioneer Investments 1,194,403 sh (+167.36%)
PRIMECAP Management 25,980,275 sh (+50.06%)
Dodge & Cox 49,613,588 sh (+17.60%)
NWQ Managers 945,170 sh (+12.55%)
Murray Stahl 28,302 sh (unchged)
Francis Chou 13,000 sh (unchged)
Manning & Napier Advisors, Inc 495,960 sh (unchged)
John Hussman 2,000 sh (unchged)
Ken Fisher 1,950,999 sh (-1.34%)
Andreas Halvorsen 2,859,129 sh (-31.53%)
Jeremy Grantham 240,631 sh (-59.54%)
Jim Simons 1,394,800 sh (-75.54%)
David Dreman 180 sh (-86.37%)
» More
Q1 2017

AZN Guru Trades in Q1 2017

Charles Brandes 236,779 sh (New)
PRIMECAP Management 34,310,950 sh (+32.07%)
Dodge & Cox 56,906,499 sh (+14.70%)
John Hussman 2,000 sh (unchged)
Murray Stahl 28,302 sh (unchged)
Steven Cohen 1,200,000 sh (unchged)
Steven Cohen Sold Out
Manning & Napier Advisors, Inc Sold Out
Francis Chou Sold Out
Andreas Halvorsen Sold Out
David Dreman Sold Out
Jeremy Grantham Sold Out
Jim Simons Sold Out
Pioneer Investments 1,185,803 sh (-0.72%)
Ken Fisher 1,921,092 sh (-1.53%)
NWQ Managers 710,935 sh (-24.78%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:LLY, NYSE:BMY, NYSE:ABBV, OTCPK:GLAXF, OTCPK:BAYRY, NYSE:SNY, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF, NAS:HCM, OTCPK:TGRNF, OTCPK:BOIRF, OTCPK:HAWPF » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, AZN.Switzerland, AZN.UK, AZNCF.USA,
Headquarter Location:UK
AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

AstraZeneca PLC was formed by merger between Astra of Sweden and Zeneca Group of the United Kingdom in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience. The majority of sales come from international markets with the United States representing slightly less than 40% of its sales.

Guru Investment Theses on AstraZeneca PLC

Dodge & Cox Comments on AstraZeneca - Feb 06, 2017

AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline.





From Dodge & Cox's Global Stock Fund 4th quarter 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Top Ranked Articles about AstraZeneca PLC

Charles Brandes Invests in Health Care in 1st Quarter Guru buys AstraZeneca, CVS, Gilead Sciences, others
Charles Brandes (Trades, Portfolio)’ Brandes Investment Partners gained 49 new holdings during the quarter. Among the purchases were several health care stocks. His three largest new health care holdings are AstraZeneca PLC (NYSE:AZN), CVS Health Corp. (NYSE:CVS) and Gilead Sciences Inc. (NASDAQ:GILD). Read more...
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
Dodge & Cox Comments on AstraZeneca Guru stock highlight
AstraZeneca (NYSE:AZN), which is based in the United Kingdom, is a global pharmaceutical company with strengths in treatment for cancer and respiratory, cardiovascular, and infectious diseases. The share price has been under pressure due to recent and upcoming patent expirations for major drugs. Despite this headwind, the long-term growth outlook is favorable because of the company’s robust new drug pipeline, particularly in oncology. AstraZeneca has an attractive position in the revolutionary field of cancer immunotherapy, which harnesses the disease -fighting capabilities of the body’s immune system to reduce and potentially eliminate cancer tumors. With a 4.6% dividend yield, the current valuation is reasonable and does not appear to reflect the potential success of the immunotherapy drug pipeline. Read more...
Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Eli Lilly has new drugs in the pipeline that will replace its failed Alzheimer treatment
Eli Lilly (NYSE:LLY) made the news for the wrong reasons on Nov. 23 after announcing that its experimental treatment for Alzheimer’s drug, Solanezumab, had failed. If it had been successful, Eli Lilly would have the distinction of researching the first effective disease modifying drug in the world. Read more...
How Could a Potential Nexium Lawsuit Affect AstraZeneca? Company's top line could suffer significantly if Nexium sales are affected by lawsuit
AstraZeneca (NYSE:AZN) is the company behind Nexium, one of the world’s most successful drugs in terms of sales. Nexium, the brand name of esomeprazole, is a proton-pump inhibitor that reduces stomach acid. It was developed in the 1990s for the purpose of treating dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. Read more...

Ratios

vs
industry
vs
history
PE Ratio 24.64
AZN's PE Ratio is ranked higher than
62% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. AZN: 24.64 )
Ranked among companies with meaningful PE Ratio only.
AZN' s PE Ratio Range Over the Past 10 Years
Min: 6.03  Med: 12.36 Max: 99.64
Current: 24.64
6.03
99.64
Forward PE Ratio 18.38
AZN's Forward PE Ratio is ranked higher than
94% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. AZN: 18.38 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 24.64
AZN's PE Ratio without NRI is ranked higher than
62% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. AZN: 24.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
AZN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.03  Med: 12.36 Max: 99.64
Current: 24.64
6.03
99.64
Price-to-Owner-Earnings 23.86
AZN's Price-to-Owner-Earnings is ranked higher than
74% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. AZN: 23.86 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.37  Med: 11.61 Max: 45.35
Current: 23.86
5.37
45.35
PB Ratio 6.25
AZN's PB Ratio is ranked lower than
73% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. AZN: 6.25 )
Ranked among companies with meaningful PB Ratio only.
AZN' s PB Ratio Range Over the Past 10 Years
Min: 2.3  Med: 3.82 Max: 6.97
Current: 6.25
2.3
6.97
PS Ratio 3.85
AZN's PS Ratio is ranked lower than
57% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. AZN: 3.85 )
Ranked among companies with meaningful PS Ratio only.
AZN' s PS Ratio Range Over the Past 10 Years
Min: 1.61  Med: 2.4 Max: 4.03
Current: 3.85
1.61
4.03
Price-to-Free-Cash-Flow 113.95
AZN's Price-to-Free-Cash-Flow is ranked lower than
69% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. AZN: 113.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AZN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.18  Med: 14.05 Max: 179.65
Current: 113.95
6.18
179.65
Price-to-Operating-Cash-Flow 27.56
AZN's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. AZN: 27.56 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AZN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.35  Med: 8.63 Max: 33.31
Current: 27.56
5.35
33.31
EV-to-EBIT 24.13
AZN's EV-to-EBIT is ranked higher than
90% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. AZN: 24.13 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 8.5 Max: 61
Current: 24.13
4.2
61
EV-to-EBITDA 15.23
AZN's EV-to-EBITDA is ranked higher than
95% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. AZN: 15.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 6.85 Max: 20.6
Current: 15.23
3.6
20.6
Shiller PE Ratio 19.79
AZN's Shiller PE Ratio is ranked higher than
86% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. AZN: 19.79 )
Ranked among companies with meaningful Shiller PE Ratio only.
AZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10  Med: 13.78 Max: 20.37
Current: 19.79
10
20.37
Current Ratio 0.75
AZN's Current Ratio is ranked lower than
92% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. AZN: 0.75 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.47 Max: 2.03
Current: 0.75
0.64
2.03
Quick Ratio 0.58
AZN's Quick Ratio is ranked lower than
87% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. AZN: 0.58 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.23 Max: 2.03
Current: 0.58
0.54
2.03
Days Inventory 217.87
AZN's Days Inventory is ranked lower than
82% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. AZN: 217.87 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.03 Max: 217.87
Current: 217.87
88.45
217.87
Days Sales Outstanding 91.68
AZN's Days Sales Outstanding is ranked higher than
78% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. AZN: 91.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.99  Med: 71.38 Max: 95.12
Current: 91.68
40.99
95.12
Days Payable 283.30
AZN's Days Payable is ranked higher than
95% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. AZN: 283.30 )
Ranked among companies with meaningful Days Payable only.
AZN' s Days Payable Range Over the Past 10 Years
Min: 128.94  Med: 186.12 Max: 397.09
Current: 283.3
128.94
397.09

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.07
AZN's Dividend Yield % is ranked higher than
94% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. AZN: 4.07 )
Ranked among companies with meaningful Dividend Yield % only.
AZN' s Dividend Yield % Range Over the Past 10 Years
Min: 2.22  Med: 4.59 Max: 7.64
Current: 4.07
2.22
7.64
Dividend Payout Ratio 1.05
AZN's Dividend Payout Ratio is ranked higher than
67% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. AZN: 1.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AZN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.56 Max: 2.89
Current: 1.05
0.4
2.89
3-Year Dividend Growth Rate 7.80
AZN's 3-Year Dividend Growth Rate is ranked higher than
51% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. AZN: 7.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AZN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -4.5  Med: 11.2 Max: 46.3
Current: 7.8
-4.5
46.3
Forward Dividend Yield % 5.54
AZN's Forward Dividend Yield % is ranked higher than
98% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. AZN: 5.54 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.36
AZN's 5-Year Yield-on-Cost % is ranked higher than
85% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. AZN: 4.36 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AZN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.38  Med: 4.92 Max: 8.19
Current: 4.36
2.38
8.19
3-Year Average Share Buyback Ratio -0.20
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. AZN: -0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 1.1 Max: 4.9
Current: -0.2
-23.3
4.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.37
AZN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. AZN: 2.37 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.48  Med: 1.36 Max: 8.67
Current: 2.37
0.48
8.67
Price-to-Median-PS-Value 1.60
AZN's Price-to-Median-PS-Value is ranked lower than
73% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. AZN: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62  Med: 1.22 Max: 2.48
Current: 1.6
0.62
2.48
Earnings Yield (Greenblatt) % 4.13
AZN's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. AZN: 4.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 11.8 Max: 23.6
Current: 4.13
1.6
23.6
Forward Rate of Return (Yacktman) % -11.14
AZN's Forward Rate of Return (Yacktman) % is ranked lower than
89% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. AZN: -11.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AZN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -17.7  Med: 18.5 Max: 27.6
Current: -11.14
-17.7
27.6

More Statistics

Revenue (TTM) (Mil) $22,292
EPS (TTM) $ 1.33
Beta0.67
Short Percentage of Float0.00%
52-Week Range $25.55 - 35.04
Shares Outstanding (Mil)2,532.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 21,647 22,460 25,510
EPS ($) 1.74 1.88 2.57
EPS without NRI ($) 1.74 1.88 2.57
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.08%
Dividends per Share ($) 1.42 1.44 1.48
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Charles Brandes Invests in Health Care in 1st Quarter May 11 2017 
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadust Mar 31 2017 
Causeway International Value Buys AstraZeneca, Gildan Mar 09 2017 
Dodge & Cox Comments on AstraZeneca Feb 06 2017 
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China Jan 30 2017 
SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors Jan 26 2017 
Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017 
Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 

More From Other Websites
AstraZeneca Initiates Voluntary Nationwide Recall of One Lot of BRILINTA 90mg Professional Sample... May 25 2017
Performance of Merck’s Diabetes Portfolio in 1Q17 May 24 2017
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk May 24 2017
The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac May 24 2017
Novo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial May 23 2017
New Research Reports for Oracle, Chubb, AstraZeneca & Others May 23 2017
AstraZeneca Sells Marketing Rights to Seloken in Europe May 23 2017
AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions May 23 2017
BYDUREON EXSCEL Trial Meets Primary Safety Objective in Type-2 Diabetes Patients at Wide Range of... May 23 2017
AstraZeneca Shares Rise as Investors Shrug Off Mixed Diabetes Results May 23 2017
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab May 22 2017
Phase III ZONDA Trial for benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma... May 22 2017
Severe asthma drug shows AstraZeneca promise beyond cancer May 22 2017
[$$] AstraZeneca sells Seloken European rights for $300m May 22 2017
AstraZeneca sells ageing beta-blocker to Recordati for $300 mln May 22 2017
Build Your Investing Watch List With Stock Ratings, Buy Zones, Earnings May 18 2017
Big Pharma Stock Astrazeneca Gets Relative Strength Upgrade May 18 2017
Vertex Pharmaceuticals' Shares Pop in Afterhours Trading After FDA Approval while AstraZeneca Sinks... May 18 2017
Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug? May 17 2017
Eli Lilly: Worries Ahead In Patent Fight May 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)